Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 72,000 |
5 mg | 在庫あり | ¥ 158,500 |
10 mg | 在庫あり | ¥ 228,000 |
25 mg | 在庫あり | ¥ 337,500 |
50 mg | 在庫あり | ¥ 454,500 |
100 mg | 在庫あり | ¥ 615,000 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 225,500 |
説明 | Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells. |
ターゲット&IC50 | BCL-XL:5.9 nM, BCL2:2 nM |
In vitro | Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells[1]. |
別名 | Bcl-2/Bcl-xl inhibitor 1, APG-2575 |
分子量 | 882.42 |
分子式 | C45H48ClN7O8S |
CAS No. | 2180923-05-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (51 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lisaftoclax 2180923-05-9 Apoptosis BCL APG2575 APG 2575 Bcl-2/Bcl-xl inhibitor 1 APG-2575 Inhibitor inhibitor inhibit